retatrutide to tirzepatide Switching from retatrutide: the complete transition guide Comparing the Big 3, Semaglutide,

Obesity causes several serious comorbidities, including type 2 diabetes, cardiovascular disease, liver disease, and chronic kidney disease

These treatments are not routinely available for weight management alone and must meet specific eligibility requirements outlined in NICE guidance

[1] [2] As of mid-2025, retatrutide has not received approval from the MHRA or EMA and remains under clinical investigation (ClinicalTrials

Importantly, these trials exhibited a high degree of heterogeneity in terms of the types of substances studied, patient characteristics, and treatment protocols, which posed significant challenges to drawing definitive conclusions

Diabetes 1996;45:832-5.ArticlePubMed 25

It replenishes moisture and helps return that healthy, radiant glow